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therapy at DLC. 20.3% of these patients had stopped PCP
prophylaxis. One patient had PCP requiring hospital admis-
sion 146 days after HCT. This patient received myeloablative
conditioning with ATG followed by mismatched unrelated
donorHCT. At timeof PCP infection, patientwas on tacrolimus
and 40mg of prednisone for GVHD treatment and was
receiving pentamidine for PCP prophylaxis.
In summary, the incidence of PCP is rare in the post alloHCT
population. Our data suggests PCP prophylaxis can be safely
discontinued if CD4+ counts > 200/uL and if not on systemic
steroids.Pre-restrictive Approach Restrictive Approach
Day 100 Mortality 2/100 3/100
1-year Mortality 11/100 8/100313
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Background: Tacrolimus has been widely used for the
prophylaxis or treatment of graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation
(HSCT). Among its side effects, nephrotoxicity is often clini-
cally problematic. Recipients of HSCTare highly susceptible to
the infectiondue todrug-resistant grampositivebacteria, and
thus nephrotoxic glycopeptide antimicrobial agents such as
teicoplanin and vancomycin are often administered. Since the
nephrotoxicity of coadministration of teicoplanin and tacro-
limus has yet to be evaluated, it was retrospectively evaluated
in the setting of allogeneic HSCT.
Patients & Methods: Recipients of allogeneic HSCT for
hematological diseases who received intravenous teicopla-
nin for more than 4 days during the continuous intravenous
infusion of tacrolimus within 30 days after transplantation
were selected from the data base. Patients who received
liposomal amphotericin-B or foscarnet were excluded. The
data including patient demographics, whole blood concen-
tration of tacrolimus, dose and duration of teicoplanin
administration, and serum creatinine (sCr) were collected.
Therapeutic drug monitoring of tacrolimus and teicoplanin
was performed in all the patients.
Results: Sixty-seven patients fulﬁlled criteria, and were
included in the analysis. Median age of the patients was 48
years (range: 16-62), and median duration of the coadmin-
istration of teicoplanin and tacrolimus was 11 days (range: 4-
40). Mean whole blood concentration of tacrolimus during
teicoplanin administration were 16.3+1.7 ng/ml. Twice or
greater increases of sCr compared with that before initiating
teicoplanin were observed only in 2 (3.0%) of 67 patients.
Nephrotoxicity was reversible andmanageable in all cases by
discontinuation of teicoplanin with or without dose adjust-
ment of tacrolimus.
Conclusion: Teicoplanin can safely be coadministered with
tacrolimus even in the early post-transplant period under
the appropriate management with therapeutic drug moni-
toring of each drug.314
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Introduction: The beneﬁts of a restrictive transfusion
approach (i.e. improved survival/ decreased infections) have
been demonstrated in a variety of hospitalized patient pop-
ulations. There are little data in the oncology setting outside
of the transplantation programs successfully treating
Jehovah Witnesses, who generally decline blood product
support. The University of Alabama at Birmingham adopted
a hospital wide restrictive transfusion policy in February,
2008; speciﬁcally in non-bleeding patients, the threshold for
transfusion is 7 g/dl and 1 unit of red cells is to be transfused
and the patient reassessed prior to considering additional
transfusions. Our stem cell transplant program adopted this
policy with the exception that patients with diastolic/systolic
dysfunction were maintained at a higher hemoglobin.
Objective: The purpose of this outcome analysis is to review
the impact of a restrictive red cell transfusion approach in
multiple myeloma patients undergoing autologous PBSC
transplant.
Materials and methods: We collected data for 200 multiple
myeloma subjects: 100 patients transplanted in 2005-2007
were compared to 100 patients who underwent trans-
plantation utilizing the restrictive transfusion policy (2009-
2011). Initial analysis included Day 100 and 1- year mortality
recognizing that the latter could be inﬂuenced bymany other
factors, including disease recurrence.
Results/Conclusion: Day 100 and 1- year mortality were not
adversely affected by the adoption of a restrictive transfusion
approach. A statistical difference was not expected as the
mortality associated with auto PBSC for multiple myeloma is
low. Further analysis of our entire multiple myeloma pop-
ulation will be presented. Analysis will include the impact of
a restrictive transfusion approach on transplant-related co-
morbidities, particularly infections. Additionally, we will
compare the number of blood products utilized in these 2
cohorts.315
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Background: HFS, an adverse reaction associated with
certain chemotherapeutic agents, is characterized by dyses-
thesias in hands and feet. No cases of HFS with total body
